Reply: Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

Lignende værker

• Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
  af: Michlmayr, A, et al.
  Udgivet: (2010)
• Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
  af: Garantziotis, S
  Udgivet: (2011)
• Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
  af: Mirzaei, Hamid Reza, et al.
  Udgivet: (2013)
• Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
  af: Exner, Ruth, et al.
  Udgivet: (2016)
• Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
  af: Medioni, Jacques, et al.
  Udgivet: (2012)